NEW YORK, April 19, 2017 /PRNewswire/ --
On Tuesday, April 18, 2017, US markets saw
Cranbury, New Jersey-based Palatin Technologies Inc.'s stock gained 18.74%, to close the day at $0.41. The stock recorded a trading volume of 8.69 million shares, which was above its three months average volume of 1.87 million shares. Palatin Technologies' shares have gained 23.87% in the last one month. The Company's shares are trading 15.57% above its 50-day moving average. Additionally, shares of the Company, which develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the US, have a Relative Strength Index (RSI) of 74.81. Visit us today and download your complete report on PTN for free at:
On Tuesday, shares in Waltham, Massachusetts headquartered AMAG Pharmaceuticals Inc. ended the session 3.60% lower at $22.75 with a total volume of 624,624 shares traded. The stock is trading 0.90% below its 50-day moving average and 12.79% below its 200-day moving average. Moreover, shares of the Company, which manufactures, develops, and commercializes therapeutics for women's health, anemia management, and cancer supportive care in the US, have an RSI of 48.55. The complimentary research report on AMAG can be accessed at:
On Tuesday, shares in Westbrook, Maine headquartered IDEXX Laboratories Inc. recorded a trading volume of 552,425 shares. The stock ended the day 0.26% higher at $155.68. Shares of the Company, which together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide, are trading at a PE ratio of 63.62. IDEXX Labs' stock has surged 2.45% in the last one month and 29.72% in the previous three months. Furthermore, the stock has rallied 94.77% in the past one year. The Company's shares are trading above its 50-day and 200-day moving averages by 4.60% and 29.08%, respectively. Furthermore, IDEXX Labs' shares have an RSI of 67.13. Register for free on Stock-Callers.com and download the PDF research report on IDXX at:
Cincinnati, Ohio headquartered Meridian Bioscience Inc.'s stock finished Tuesday's session 1.47% lower at $13.40 with a total volume of 185,104 shares traded. The Company's shares are trading above its 50-day moving average by 2.31%. Shares of Meridian Bioscience, which develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal, viral, respiratory, and parasitic infectious diseases worldwide, are trading at a PE ratio of 19.23. The stock has an RSI of 51.60.
On March 28th, 2017, research firm CL King initiated a 'Neutral' rating on the Company's stock. Get free access to your research report on VIVO at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...
Benign prostatic hyperplasia or enlarged prostate is a noncancerous condition observed in men above ...
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...View All